A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
暂无分享,去创建一个
H. Gundacker | F. Appelbaum | C. Willman | T. Norwood | J. Lancet | J. Liesveld | A. Advani | M. Sekeres | S. Petersdorf | A. List | D. Mulford
[1] A. Jankowska,et al. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide , 2012, Journal of Hematology & Oncology.
[2] R. Vij,et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia , 2011 .
[3] J. Maciejewski,et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes , 2011, American journal of hematology.
[4] M. Grever,et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. O'keefe,et al. Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q) , 2010 .
[6] H. Dombret,et al. Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM) , 2010 .
[7] K. Götze,et al. A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial , 2010 .
[8] J. Gamble,et al. Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells. , 2010, Blood.
[9] Клинические дисциплины. Cancer and Leukemia Group B , 2010 .
[10] J. Burger. Angiopoietin-2 in CLL. , 2010, Blood.
[11] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Petersen,et al. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT , 2010, Bone Marrow Transplantation.
[13] J. Issa,et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.
[14] J. Byrd,et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.
[15] A. Stamatoullas,et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. , 2009, Blood.
[16] T. Golub,et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.
[17] M. Gordon. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .
[18] A. Advani,et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia , 2007, Cancer.
[19] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[20] J. Lancet,et al. Treatment of deletion 5q acute myeloid leukemia with lenalidomide , 2007, Leukemia.
[21] D. Steensma,et al. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome , 2006, Leukemia.
[22] Yi Ning,et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.
[23] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[24] C. Earle,et al. Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly , 2005, Drugs & aging.
[25] R. Stone,et al. Acute myeloid leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[26] D. Neuberg,et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.
[27] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Caligiuri,et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.
[29] M. Fridkin,et al. Adhesion of human platelets to serum amyloid A. , 2002, Blood.
[30] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[31] R. Clark,et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[32] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[33] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[34] Stephen L. George,et al. Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .
[35] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[36] H. Tilly,et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .